Global pioneers of convenient treatment for allergy and immune related disorders.
Committed to transforming lives by breaking new ground in immunology treatment.
We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.
We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms.
Our vaccines are aluminium free and our short course treatments make life easier and support adherence.
Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease.
We are a proud and passionate team of scientists and business specialists with a vision that delivers growth and transforms the way we think about disease.
Allergies reduce quality of life by preventing individuals and their loved ones from enjoying the everyday activities most take for granted. At their most severe, they can be fatal.
Whatever the severity of an allergy, the wider implications are negative. Many patients and their families live in fear and can feel isolated or excluded.
There's no doubt that our work in allergy treatment is transforming lives.
We think beyond symptom management and aim to treat the causes. Together we're changing the way people think about allergy.
Through innovative adjuvant technologies we create therapies that act faster and work more efficiently. What's more, we are using this knowledge outside allergy treatment.
For example, our work is helping to develop vaccinations for infectious disease and cancer treatments. So through the many immunology firsts we've achieved, we're transforming lives around the world.
To achieve our vision and fulfil our mission, we develop treatments that are as convenient as they are effective.
Many patients and their healthcare providers find current medications are difficult to administer and adhere to.
According to studies into the compliance of allergen immunotherapy treatments, a major cause of non-compliance was inconvenience. Some treatments involve a long course of injections. Our short course treatments take only 4 to 6 injections over the course of 3 to 6 weeks.
Specialist expertise drives and inspires us to discover more, helping us to improve patients' lives.
Our culture has always been to define the market through insight and innovation. Through this sense of discovery, we find new opportunities to resolve wider global healthcare issues.
Our business is built on a legacy of strong financial success, plus a track-record of bringing products to market effectively.
We've developed adjuvant technologies that make allergy treatment more efficient than ever and are also breaking new ground in the research of infectious disease and cancer.
Our short course treatments take 4 - 6 injections, over the course of 3 - 6 weeks. Alternative therapies in the USA can take 50-100 injections and up to 15 in countries across Europe.
Treating the cause for a comparable cost to one that merely manages the symptoms seems compelling to us.
We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in preclinical development.
Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. They improve therapies by allowing them to act faster and we now help others by using this knowledge; improving health and developing vaccinations for infectious disease and cancer treatments.
Through our Bencard Adjuvant Systems division we are engaging in long-term partnerships with those who require our patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development.
Our Adjuvant Systems
Research and Development
R&D Senior Management Team
Our research and development group is organised with key senior managers leading the following areas of the investigational product lifecycle:
Our early phase (phase I/II) clinical development programme is led by Head of Clinical Sciences Simon Piggott.
Our late phase (phase II/III) clinical development programme is led by Head of Clinical Operations Denise Lee.
The recent appointment of Simon Piggott and planned growth within Simon and Denise’s teams will allow us to realise our ambitious plans for clinical development in Europe.
Our US programme is led by Clinical Director Pieter-Jan de Kam. Pieter-Jan is responsible for clinical development of products for the US market.
For more information please click here
Meet the members of our Board of Directors. They have wide commercial and technical experience in pharmaceutical product and business development, finance and R&D.
Peter joined the Board in October 2010 and was appointed Non-Executive Chairman on 1st January 2011. As Non-Executive Chairman, Peter is responsible for the leadership of the Board by ensuring clear company strategy, board effectiveness, good corporate governance and effective communication with shareholders. Peter held a number of senior roles in his 21 years with SmithKline-Beecham. Between 1994 and 1998, he was Chairman of Consumer Healthcare Europe. Then between 1998 and 2001 he held the position of President of Worldwide Supply Operations, based in Philadelphia.
Since leaving SmithKline-Beecham at the time of the merger with Glaxo, Peter has held a number of non-executive director and chairman roles for various public and private companies. These include Domino Printing Sciences plc, Glenmorangie plc, Genetix Group plc, Celsis International plc and Victoria plc. In addition to his role at Allergy Therapeutics, Peter is currently Chairman of Nottingham Racecourse, Screendragon Limited, The Home of Horseracing Trust Limited and The British Sporting Art Trust and is a director of The Osborne Studio Gallery Limited.
Peter chairs the Nomination Committee and is also a member of the Audit Committee.
Stephen is a Chartered Management Accountant, Fellow of the Association of Corporate Treasurers and Member of the Institute for Turnaround. Since 1995, he has operated as an independent executive, Non-Executive Director and interim manager (CRO/CEO/COO/FD) on an international basis. Up to 1995, Stephen held various senior financial positions in UK-based international public companies, including 6 years as Group Treasurer of The Rank Organisation and 3 years as Group Finance Director of a quoted hotel company. Stephen chairs the Audit and Remuneration Committees, is a member of the Nomination Committee that he chaired until 1st January 2011 and is the Senior Non-Executive Director.
Tunde joined the Board in June 2017 bringing over 20 years’ pharmaceutical industry knowledge and significant executive level experience in clinical development and medical affairs roles.
He currently serves as Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals where he has responsibility for all global medical functions, and has previously worked for Boehringer Ingelheim Pharmaceutical Inc. as Senior Vice President, Clinical Development and Medical Affairs.
He has previously spent over six years working at the US Food and Drug Administration (FDA) as a Medical Officer and Medical Team Leader in the Division of Pulmonary-Allergy Drug Products.
Jeff has been nominated to the Board by Abbott Laboratories and is currently Vice President, Licensing and Acquisitions at Abbott. During his time in this role, Abbott has executed several strategically important transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm. He joined Abbott in 1990 and during his career has held a variety of financial management positions across their businesses, including in Diagnostics, Nutrition and Pharmaceuticals.
Mr Barton holds a degree in accounting from Indiana University, and a Masters of Management from the Northwestern University Kellogg Graduate School of Management.
Chief Executive Officer
Manuel joined the group in July 2009 following the successful refinancing in which Azure Ventures Limited was the main investor. Prior to this appointment, Manuel was the Principal Consultant for Biohealth LLC and CEO of International Operations of the Weinstein family’s group of companies. Manuel was responsible for international development of the Weinstein family’s group of pharmaceutical companies in 20 countries. Manuel has over ten years’ experience working in the pharmaceutical industry, primarily in South America.
During this time he served as Executive Director of Corporación Drokasa, where he was responsible for a US$25 million AAA-rated bond issue to finance the group’s expansion plans; CEO of Laboratorios Andrómaco, where he led the group to an IPO on the Santiago Stock Exchange; and Business Development Manager for Laboratorio Chile. Manuel participated in the Executive Program at the Graduate Business School of Stanford University and has an MBA from IESE, Universidad de Navarra in Barcelona. Manuel also has degrees in Industrial Business Management and Chemical Engineering from Universitat Ramon Llull in Barcelona.
As Chief Executive Officer, Manuel is responsible for the executive management of group operations, investor relations, and implementation of the Board’s collective decisions overseeing all operational aspects of the Group and directing the long-term strategy.
Nick joined Allergy Therapeutics on 9th June 2016 as Finance Director. Nick was most recently at Skyepharma PLC until August 2015 where he was the Group Financial Controller for six years. Prior to that, he had also worked at Quest International (a part of ICI PLC) as the Group Financial Controller (Special Projects), following six years at Deloitte & Touche. Nick has a BSc (Hons) in Economics and is a qualified accountant, being a member of the Institute of Chartered Accountants of England and Wales.
Or call us on:
Tel +44 (0)1903 844 700
|Shareholder Name||Amount||% Holding|
|CFR International SPA & Associated Holding||240,584,571||40.49|
|Southern Fox Investments||127,283,783||21.42|
|Odey Asset Management||43,747,523||7.36|
|Invesco Asset Management||34,110,209||5.74|
|Black Rock Investment Management||30,368,413||5.11|
|Director Name||Amount||% Holding|
Nomad and Broker: Panmure Gordon (UK) Limited
Panmure Gordon & Co
One New Change
Bank: Royal Bank of Scotland PLC
21 Broad Street
Auditor: Grant Thornton UK LLP
Grant Thornton House
Financial PR: Consilium Strategic Communications
Solicitors: Covington & Burling LLP & Cotley LLP
Cooley (UK) LLP
69 Old Broad Street